1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
FEATURED COMPANIES
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Merck & Co., Inc.
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
The increasing prevalence of STDs is one of the key factors expected to trigger the market’s growth in the forthcoming years. STDs are rising in the emerging and advanced economies, resulting in the rising demand for drugs and therapies for treating these chronic illnesses. The cases of these incidences has increased considerably in the recent years owing to the transmission of different bacteria, viruses, and parasites during sexual contact. As a result, the increasing prevalence of STDs will further propel the demand for drugs and therapies, in turn, contributing significantly to the STD treatment market growth during the forecast period. The analysts have predicted that the sexually transmitted diseases (STD) treatment market will register a CAGR of more than 4% by 2023.
Market Overview
Approval of drugs and a strong pipeline
One of the growth drivers of the global sexually transmitted diseases (STD) treatment market is the approval of drugs and a strong pipeline. With the increase in prevalence and incidence of STDs, market players are focused on the development of therapies to treat these diseases. The market has witnessed new drug approvals, which will drive the market during the forecast period.
Social stigma associated with STDs
One of the challenges in the growth of the global sexually transmitted diseases (STD) treatment market is the social stigma associated with STDs. The social stigma associated with STDs can lead to reduced screening, prevention, and care, thereby hindering the growth of the market.
For the detailed list of factors that will drive and challenge the growth of the sexually transmitted diseases (STD) treatment market during 2019-2023, view this report.
Competitive Landscape
The market appears to be moderately fragmented with the presence of several market players. Many government organizations are collaborating with commercial companies to develop HIV vaccines. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Market Overview
Approval of drugs and a strong pipeline
One of the growth drivers of the global sexually transmitted diseases (STD) treatment market is the approval of drugs and a strong pipeline. With the increase in prevalence and incidence of STDs, market players are focused on the development of therapies to treat these diseases. The market has witnessed new drug approvals, which will drive the market during the forecast period.
Social stigma associated with STDs
One of the challenges in the growth of the global sexually transmitted diseases (STD) treatment market is the social stigma associated with STDs. The social stigma associated with STDs can lead to reduced screening, prevention, and care, thereby hindering the growth of the market.
For the detailed list of factors that will drive and challenge the growth of the sexually transmitted diseases (STD) treatment market during 2019-2023, view this report.
Competitive Landscape
The market appears to be moderately fragmented with the presence of several market players. Many government organizations are collaborating with commercial companies to develop HIV vaccines. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Merck & Co., Inc.
PART 01: EXECUTIVE SUMMARYPART 07: CUSTOMER LANDSCAPEPART 09: DECISION FRAMEWORKPART 11: MARKET TRENDS
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY TYPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
List of Exhibits
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Merck & Co., Inc.
Global Sexually Transmitted Diseases (STD) Treatment Market 2019-2023
The analyst recognizes the following companies as the key players in the global sexually transmitted diseases (STD) treatment market: Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., and Merck & Co., Inc.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the advances in the rapid diagnosis of STDs.”
According to the report, one of the major drivers for this market is the initiatives to increase funding and awareness about STDs.
Further, the report states that one of the major factors hindering the growth of this market is the high cost of novel antiviral therapeutics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
The analyst recognizes the following companies as the key players in the global sexually transmitted diseases (STD) treatment market: Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., and Merck & Co., Inc.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the advances in the rapid diagnosis of STDs.”
According to the report, one of the major drivers for this market is the initiatives to increase funding and awareness about STDs.
Further, the report states that one of the major factors hindering the growth of this market is the high cost of novel antiviral therapeutics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
Note: Product cover images may vary from those shown
